Literature DB >> 18025131

Tuberculosis and its future management.

John C Moore-Gillon1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 18025131      PMCID： PMC2094282          DOI： 10.1136/thx.2007.090936

Source DB:  PubMed          Journal:  Thorax        ISSN： 0040-6376            Impact factor:   9.139


× No keyword cloud information.
  14 in total

1.  A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis.

Authors:  Koen Andries; Peter Verhasselt; Jerome Guillemont; Hinrich W H Göhlmann; Jean-Marc Neefs; Hans Winkler; Jef Van Gestel; Philip Timmerman; Min Zhu; Ennis Lee; Peter Williams; Didier de Chaffoy; Emma Huitric; Sven Hoffner; Emmanuelle Cambau; Chantal Truffot-Pernot; Nacer Lounis; Vincent Jarlier
Journal:  Science       Date:  2004-12-09       Impact factor: 47.728

Review 2.  Exploiting immunology and molecular genetics for rational vaccine design against tuberculosis.

Authors:  S H E Kaufmann; S Baumann; A Nasser Eddine
Journal:  Int J Tuberc Lung Dis       Date:  2006-10       Impact factor: 2.373

3.  Application of the Capilia TB assay for culture confirmation of Mycobacterium tuberculosis complex isolates.

Authors:  D Hillemann; S Rüsch-Gerdes; E Richter
Journal:  Int J Tuberc Lung Dis       Date:  2005-12       Impact factor: 2.373

4.  Planning to improve global health: the next decade of tuberculosis control.

Authors:  Dermot Maher; Chris Dye; Katherine Floyd; Andrea Pantoja; Knut Lonnroth; Alasdair Reid; Eva Nathanson; Thad Pennas; Uli Fruth; Jane Cunningham; Heather Ignatius; Mario C Raviglione; Irene Koek; Marcos Espinal
Journal:  Bull World Health Organ       Date:  2007-05       Impact factor: 9.408

Review 5.  From magic bullets back to the magic mountain: the rise of extensively drug-resistant tuberculosis.

Authors:  Susan E Dorman; Richard E Chaisson
Journal:  Nat Med       Date:  2007-03       Impact factor: 53.440

Review 6.  Challenges in tuberculosis drug research and development.

Authors:  Ann M Ginsberg; Melvin Spigelman
Journal:  Nat Med       Date:  2007-03       Impact factor: 53.440

7.  TB on the back burner, losing curable status.

Authors:  Tony Moll
Journal:  Int J Tuberc Lung Dis       Date:  2007-04       Impact factor: 2.373

8.  Microscopic-observation drug-susceptibility assay for the diagnosis of TB.

Authors:  David A J Moore; Carlton A W Evans; Robert H Gilman; Luz Caviedes; Jorge Coronel; Aldo Vivar; Eduardo Sanchez; Yvette Piñedo; Juan Carlos Saravia; Cayo Salazar; Richard Oberhelman; Maria-Graciela Hollm-Delgado; Doris LaChira; A Roderick Escombe; Jon S Friedland
Journal:  N Engl J Med       Date:  2006-10-12       Impact factor: 91.245

9.  Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa.

Authors:  Neel R Gandhi; Anthony Moll; A Willem Sturm; Robert Pawinski; Thiloshini Govender; Umesh Lalloo; Kimberly Zeller; Jason Andrews; Gerald Friedland
Journal:  Lancet       Date:  2006-11-04       Impact factor: 79.321

10.  Identification of diagnostic markers for tuberculosis by proteomic fingerprinting of serum.

Authors:  Dan Agranoff; Delmiro Fernandez-Reyes; Marios C Papadopoulos; Sergio A Rojas; Mark Herbster; Alison Loosemore; Edward Tarelli; Jo Sheldon; Achim Schwenk; Richard Pollok; Charlotte F J Rayner; Sanjeev Krishna
Journal:  Lancet       Date:  2006-09-16       Impact factor: 79.321
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.